The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment. They have shown that serum assays for the proteases and protease inhibitor can be used for early detection of ovarian cancer, and for monitoring cancer treatment.

The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment. They have shown that serum assays for the proteases and protease inhibitor can be used for early detection of ovarian cancer, and for monitoring cancer treatment.

Herein is reported a method for the detection of a sortase in a sample, comprising the following steps: a) incubating the sample with a first substrate comprising an immobilization tag and a second substrate comprising a detectable label, whereby in the presence of a sortase in the sample a conjugate comprising the immobilization tag and the detectable label is formed, b) immobilizing the conjugate of step a) via/using the immobilization tag to a solid phase, c) detecting the immobilized conjugate via/using the detectable label
and thereby detecting the sortase in the sample.

A fluid sample container comprising a protease, when a sample fluid is placed in the fluid sample container the protease breaking a target analyte in the sample fluid into at least two peptides, the at least two peptides being smaller than the original target analyte.

A fluid sample container comprising a protease, when a sample fluid is placed in the fluid sample container the protease breaking a target analyte in the sample fluid into at least two peptides, the at least two peptides being smaller than the original target analyte.

The present invention relates to a diagnostic peptide and methods, kits and systems for the in vitro diagnostic of an infection in a subject. The methods using the peptide of the invention comprise the steps of: i) providing a bodily fluid sample, ii) contacting the bodily fluid sample with a peptide comprising a fluorescent agent having an emission wavelength of 650-900 nm and a non-fluorescent agent having an absorption wavelength of 650-900 nm, for quenching said emission of said fluorescent agent, and a cleavage site located between said fluorescent agent and first non-fluorescent agent, the cleavage site being specific for a viral protease, iii) monitoring the fluorescence in the range of 650-900 nm from the peptide in step ii), wherein an increase in fluorescence in the range of 650-900 nm is indicative for the presence of a viral protease in the sample.

The present invention relates to a diagnostic peptide and methods, kits and systems for the in vitro diagnostic of an infection in a subject. The methods using the peptide of the invention comprise the steps of: i) providing a bodily fluid sample, ii) contacting the bodily fluid sample with a peptide comprising a fluorescent agent having an emission wavelength of 650-900 nm and a non-fluorescent agent having an absorption wavelength of 650-900 nm, for quenching said emission of said fluorescent agent, and a cleavage site located between said fluorescent agent and first non-fluorescent agent, the cleavage site being specific for a viral protease, iii) monitoring the fluorescence in the range of 650-900 nm from the peptide in step ii), wherein an increase in fluorescence in the range of 650-900 nm is indicative for the presence of a viral protease in the sample.

The present disclosure provides materials and methods for determining the presence of an N-terminal modification on a therapeutic protein, and/or the efficiency of N-terminal modification, such as PEGylation, at the N-terminus of a therapeutic protein such as Filgrastim (wherein the PEGylated version is therefore Pegfilgrastim).

The present disclosure provides materials and methods for determining the presence of an N-terminal modification on a therapeutic protein, and/or the efficiency of N-terminal modification, such as PEGylation, at the N-terminus of a therapeutic protein such as Filgrastim (wherein the PEGylated version is therefore Pegfilgrastim).

Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.